Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma

NCT07657325 · clinicaltrials.gov ↗

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)

Interventions

DRUG: Toripalimab

Sponsor

Tianjin Medical University Second Hospital